CD33 and acute myeloid leukemia: Both extracellular (CD33, LeY, CD123, FLT3, CLL1, NKG2D, CD44v6, CD38, and CD7) and intracellular (PR1 and WT-1, etc.)markers have been reported as target molecules for CAR-T therapy against AML [113].